A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Part of paid clinical trials in Modesto, California.

Sponsor
Pfizer
Study ID
NCT07595549
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PF-08653944 — DRUG
    By Subcutaneous Injection
  • Placebo — OTHER
    By Subcutaneous Injection

Study Details

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.

Key Dates

First listed
May 19, 2026
Start date
Jun 10, 2026
Status verified
Jul 2026
Primary completion
May 4, 2028
Completion
Jun 21, 2028

Study Design

Enrollment
954 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Arm 1
    Participants will receive PF-08653944 by Subcutaneous Injection.
  • Experimental: Treatment Arm 2
    Participants will receive PF-08653944 by Subcutaneous Injection.
  • Experimental: Treatment Arm 3
    Participants will receive PF-08653944 by Subcutaneous Injection.
  • Experimental: Treatment Arm 4
    Participants will receive PF-08653944 by Subcutaneous Injection.
  • Placebo Comparator: Placebo
    Participants will receive matching placebo by Subcutaneous Injection.

Primary Outcome Measure

Percent change from baseline in body weight [ Time Frame: Baseline, Week 72 ]

Central Contacts

Locations (20)

FacilityCityStateZIPSite coordinators
ImmuniMet, LLCModestoCalifornia95350-
ClearVue Eye CareRosevilleCalifornia95661-
Clinical Trials ResearchSacramentoCalifornia95821-
University Clinical Investigators, Inc.TustinCalifornia92780-
Diablo Clinical Research, Inc.Walnut CreekCalifornia94598-
Nature Coast Clinical ResearchCrystal RiverFlorida34429-
West Coast Eye InstituteLecantoFlorida34461-
South Broward ResearchMiramarFlorida33027-
Suncoast Clinical Research, Inc.New Port RicheyFlorida34652-
West Coast Medical AssociatesNew Port RicheyFlorida34652-
MediSphere Medical Research Center, LLCEvansvilleIndiana47714-
Monroe Biomedical ResearchLouisvilleKentucky40213-
Aa Mrc LlcFlintMichigan48504-
Albuquerque Clinical Trials, Inc.AlbuquerqueNew Mexico87102-
Rochester Clinical Research, LLCRochesterNew York14609-
Medication Management LLCGreensboroNorth Carolina27405-
Midwest Eye CenterCincinnatiOhio45202-
Velocity Clinical Research, Mt. AuburnCincinnatiOhio45219-
VIP TrialsSan AntonioTexas78230-
York Clinical Research, LLCNorfolkVirginia23504-

Find similar trials in Modesto, CA

Nationwide
Obesity / overweight trialsEndocrinology trialsMetabolic health trialsWeight loss trials
By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
ImmuniMet, LLC· Modesto, CAClearVue Eye Care· Roseville, CAClinical Trials Research· Sacramento, CAUniversity Clinical Investigators, Inc.· Tustin, CADiablo Clinical Research, Inc.· Walnut Creek, CANature Coast Clinical Research· Crystal River, FL

Related Studies